#USA #Securities Law #DJS Law Group #Eastchester #ADMA Biologics

DJS Law Group Announced Class Action Against ADMA Biologics, Inc.

In an important update, the DJS Law Group is reminding investors about an ongoing class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA). This legal action concerns significant allegations against the company for violations of securities laws, specifically §§ 10(b) and 20(a) of the Securities Exchange Act of 1934, along with Rule 10b-5 as established by the U.S. Securities and Exchange Commission.

Case Background

The class action lawsuit covers a period from August 9, 2024, to March 25, 2026. During this timeframe, shareholders who purchased ADMA’s stocks may have been adversely affected due to what the lawsuit claims are false and misleading statements made by the company. Allegations suggest that ADMA failed to disclose essential information concerning a related party transaction. Additionally, it’s asserted that the company inflated sales figures to portray a more favorable market position than what was actually the case.

According to the complaint, these misleading public statements created a false narrative about the company's performance and financial health. This situation has led to a decline in shareholder confidence and is believed to have resulted in losses among investors.

Investor Participation

If you have purchased shares of ADMA during the specified class period and feel that you have experienced financial harm due to the company’s misrepresentation, the DJS Law Group encourages you to reach out to them for a consultation. Importantly, potential lead plaintiff appointments are available, but being appointed as a lead plaintiff is not a requirement to participate in seeking recovery.

Why Choose DJS Law Group?

DJS Law Group specializes in advocating for investor rights and has a dedicated focus on negotiating favorable outcomes for clients. They excel in handling securities class actions and corporate governance litigation, which sets them apart in the field of investor advocacy. Their client roster includes some of the largest hedge funds and asset managers worldwide, underscoring their expertise and value in litigation.

The firm understands the complexities involved in securities litigation and is poised to provide steady guidance to affected shareholders. Their goal is to enhance investor returns through methodical legal strategies and robust representation.

Next Steps for Affected Investors

Shareholders who suffered losses related to ADMA Biologics should not hesitate to contact DJS Law Group. Taking action quickly can ensure your rights and interests are adequately protected. The established deadline for participating in this lawsuit is August 10, 2026, emphasizing the urgency for individuals who believe they may have a case.

If you seek more information or wish to discuss your potential claims, please contact:

DJS Law Group
David J. Schwartz
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]

This announcement stands as an essential note for investors navigating the complications arising from securities violations. Legal avenues are open for those affected, and it’s advisable to seek professional legal counseling to understand the potential for recovering losses due to misleading corporate practices.

Stay vigilant and informed about your rights as a shareholder, especially in light of the evolving legal landscape surrounding securities regulations.